<!DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Strict//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-strict.dtd"><html xml:lang="en" lang="en" xmlns="http://www.w3.org/1999/xhtml"><head><meta http-equiv="Content-Type" content="text/html; charset=utf-8" /><meta name="ROBOTS" content="NOARCHIVE" /><meta name="googlebot" content="nosnippet" /><meta name="Document-Type" content="sub-topic" /><meta name="keywords" content="Anorexia: palliative care; Prednisolone: palliative care; Dexamethasone: anorexia, palliative care; Respiratory: secretions, excessive, palliative care; Colic, bowel, palliative care; Hyoscine hydrobromide: palliative care: excessive respiratory secretions; Hyoscine hydrobromide: palliative care: bowel colic; Hyoscine butylbromide: palliative care: bowel colic; Hyoscine butylbromide: palliative care: excessive respiratory secretions; Glycopyrronium bromide: palliative care; Capillary bleeding, palliative care; Tranexamic acid: palliative care; Adrenaline: capillary bleeding, palliative care; Vitamin K: palliative care; Constipation: palliative care; Laxatives: palliative care; Methylnaltrexone: palliative care; Convulsions: palliative care; Phenytoin: convulsions, palliative care; Carbamazepine: palliative care; Diazepam: convulsions, palliative care; Phenobarbital: convulsions, palliative care; Dry mouth: palliative care; Artificial saliva: palliative care; Nystatin: mouth: palliative care; Miconazole: mouth: palliative care; Fluconazole: mouth: palliative care; Dysphagia, palliative care; Dexamethasone: dysphagia, palliative care; Dyspnoea, palliative care; Diazepam: dyspnoea, palliative care; Dexamethasone: dyspnoea, palliative care; Tumour, fungating; Metronidazole: skin: fungating tumours; Hiccup: palliative care; Antacids: palliative care; Metoclopramide: hiccup, palliative care; Baclofen: palliative care; Nifedipine: palliative care; Chlorpromazine: hiccup; Insomnia: palliative care; Benzodiazepines: hypnotics: palliative care; Cough: palliative care; Morphine: cough: palliative care; Nausea: palliative care; Vomiting: palliative care; Antiemetics: palliative care; Metoclopramide: nausea and vomiting: palliative care; Haloperidol: palliative care; Cyclizine: palliative care; Levomepromazine: palliative care; Dexamethasone: nausea and vomiting: palliative care; Pruritus: palliative care; Emollients: pruritus, palliative care; Colestyramine: pruritus: palliative care; Intracranial pressure, raised: palliative care; Dexamethasone: raised intracranial pressure, palliative care; Restlessness, palliative care; Confusion, palliative care; Haloperidol: palliative care; Levomepromazine: palliative care" /><meta name="IX" content="Anorexia: palliative care; Prednisolone: palliative care; Dexamethasone: anorexia, palliative care; Respiratory: secretions, excessive, palliative care; Colic, bowel, palliative care; Hyoscine hydrobromide: palliative care: excessive respiratory secretions; Hyoscine hydrobromide: palliative care: bowel colic; Hyoscine butylbromide: palliative care: bowel colic; Hyoscine butylbromide: palliative care: excessive respiratory secretions; Glycopyrronium bromide: palliative care; Capillary bleeding, palliative care; Tranexamic acid: palliative care; Adrenaline: capillary bleeding, palliative care; Vitamin K: palliative care; Constipation: palliative care; Laxatives: palliative care; Methylnaltrexone: palliative care; Convulsions: palliative care; Phenytoin: convulsions, palliative care; Carbamazepine: palliative care; Diazepam: convulsions, palliative care; Phenobarbital: convulsions, palliative care; Dry mouth: palliative care; Artificial saliva: palliative care; Nystatin: mouth: palliative care; Miconazole: mouth: palliative care; Fluconazole: mouth: palliative care; Dysphagia, palliative care; Dexamethasone: dysphagia, palliative care; Dyspnoea, palliative care; Diazepam: dyspnoea, palliative care; Dexamethasone: dyspnoea, palliative care; Tumour, fungating; Metronidazole: skin: fungating tumours; Hiccup: palliative care; Antacids: palliative care; Metoclopramide: hiccup, palliative care; Baclofen: palliative care; Nifedipine: palliative care; Chlorpromazine: hiccup; Insomnia: palliative care; Benzodiazepines: hypnotics: palliative care; Cough: palliative care; Morphine: cough: palliative care; Nausea: palliative care; Vomiting: palliative care; Antiemetics: palliative care; Metoclopramide: nausea and vomiting: palliative care; Haloperidol: palliative care; Cyclizine: palliative care; Levomepromazine: palliative care; Dexamethasone: nausea and vomiting: palliative care; Pruritus: palliative care; Emollients: pruritus, palliative care; Colestyramine: pruritus: palliative care; Intracranial pressure, raised: palliative care; Dexamethasone: raised intracranial pressure, palliative care; Restlessness, palliative care; Confusion, palliative care; Haloperidol: palliative care; Levomepromazine: palliative care" /><title>Miscellaneous conditions: British National Formulary</title><link type="text/css" rel="stylesheet" href="../../theme/theme.css" /><link type="text/css" rel="stylesheet" href="../../theme/print.css" media="print" /><link type="text/css" rel="stylesheet" href="59/style.css" /><link type="image/x-icon" rel="shortcut icon" href="favicon.ico" /><link rel="stylesheet" type="text/css" href="style/screen.css" media="screen" /><link rel="stylesheet" type="text/css" href="style/print.css" media="print" /><link rel="contents" type="text/html" href="index.htm" /><link rel="help" type="text/html" href="http://www.medicinescomplete.com/mc/help_page.htm" /><link rel="start" type="text/html" href="index.htm" title="British National Formulary" /><link rel="copyright" type="text/html" href="PHP0-publication-information.htm" title="Copyright information" /><link rel="bookmark" title="Skip Navigation" href="PHP120-miscellaneous-conditions.htm#pB" /><script type="text/javascript" src="https://ajax.googleapis.com/ajax/libs/jquery/1.7.0/jquery.min.js"></script><script type="text/javascript" src="../../scripts/jquery/jquery.tooltip.min.js"></script><script type="text/javascript" src="../../scripts/jquery/jquery.cookie.js"></script><script type="text/javascript" src="../../scripts/jquery/jquery.autosuggest.js"></script><script type="text/javascript" src="../../scripts/scripts.js"></script><style type="text/css">
  .contentsbox { position: fixed; z-index:1001;}
  .contentsbox_wrap {overflow:hidden;width:20px;height:130px; position:absolute;left:0;top:0;}
</style><!--[if lte IE 7]>
          <style type="text/css">
          .contentsbox {
          position: absolute;
          left: expression( ( 15 + ( ignoreMe2 = document.documentElement.scrollLeft ? document.documentElement.scrollLeft : document.body.scrollLeft ) ) + 'px' );
          top: expression( ( 250 + ( ignoreMe = document.documentElement.scrollTop ? document.documentElement.scrollTop : document.body.scrollTop) ) + 'px' );
          }
          .threecol_col3 {
          font-family: arial
          }
          .threecol_col3 a {
          font-family: verdana,helvetica,sans-serif
          }
          .threecol_col1 {
          font-family: arial
          }
          .threecol_col1 a {
          font-family: verdana,helvetica,sans-serif
          }
          div#pE {
          font-family: arial
          }
          div#pE a {
          font-family: verdana,helvetica,sans-serif
          }
          div#pK {
          font-family: arial
          }
          div#pK a {
          font-family: verdana,helvetica,sans-serif
          }
          </style>
          <![endif]--></head><body><?highlighter off?><div id="pU"><a id="pD" accesskey="s" rel="bookmark" href="PHP120-miscellaneous-conditions.htm#pB" title="Skip Navigation">Skip Navigation</a><img src="../../images/mylogo.png" alt="BNF.org Free Access" id="pI" /><ul id="pZ"><li><a href="http://www.medicinescomplete.com/mc/account.htm">You are signed in as a member of <b>BNF.org Free Access</b></a></li><li> | <a href="http://www.medicinescomplete.com/mc/login.htm">Sign in different user</a></li><li> | <a href="http://www.medicinescomplete.com/mc/logout.htm">Sign out</a></li></ul><a href="http://www.medicinescomplete.com/mc/" title="Go to the MedicinesComplete home page"><img src="../../images/mc.png" alt="MedicinesComplete" /></a><ul id="pM"><li><a href="http://www.medicinescomplete.com/mc/" class="selected" accesskey="1" title="Home: access key 1"><strong><span>Home</span></strong></a></li><li><a href="http://www.medicinescomplete.com/mc/marketing/current/"><strong><span>Welcome</span></strong></a></li><li><a href="http://www.medicinescomplete.com/mc/feedback.htm?pub=bnf&amp;uri=PHP120-miscellaneous-conditions.htm" accesskey="9" title="Feedback: access key 9"><strong><span>Feedback</span></strong></a></li><li><a href="http://www.medicinescomplete.com/mc/help.htm" accesskey="6" title="Help button: access key 6"><strong><span>Help</span></strong></a></li></ul></div><div id="pA"><div id="pY">British National Formulary</div><div id="pG">Printed from: Joint Formulary Committee.  <i>British National Formulary</i>. [online] London: BMJ Group and Pharmaceutical Press.. &lt; http://www.medicinescomplete.com/ &gt; [Accessed on 06 Oct 2012 (GMT)].</div><div id="pQ"><form id="searchForm" method="get" action="http://www.medicinescomplete.com/mc/bnf/current/search.htm"><fieldset><legend>Details</legend><label for="q">Search for</label><div id="qd"><div><input accesskey="4" type="text" id="q" name="q" /><input class="button" id="searchButton" type="submit" value="Search" name="searchButton" title="Search full text" /></div></div></fieldset></form><script type="text/javascript">$(document).ready(function(){$("#q").autoSuggest('http://www.medicinescomplete.com/mc/bnf/current/search/suggest.xml', {control: "#searchButton"});});</script></div></div><div id="pH"><div id="pN"><div id="pT"><span class="cA"><a href="http://www.medicinescomplete.com/mc/">Home</a></span> &gt; <a href="index.htm">BNF September 2012</a> &gt; <a href="PHP59-guidance-on-prescribing.htm">Guidance on prescribing</a> &gt; <a href="PHP113-prescribing-in-palliative-care.htm">Prescribing in palliative care</a></div><div id="pP"><div class="threecol_col1">◄ <a accesskey="[" href="PHP114-pain.htm" title="Previous: Pain">Previous page</a></div><div class="threecol_col2"> </div><div class="threecol_col3"><a accesskey="]" href="PHP130-continuous-infusion-devices.htm" title="Next: Continuous infusion devices">Next page</a> ►</div></div></div></div><div id="p1"><div id="pB"><h1>Miscellaneous conditions</h1><?highlighter on?><div id="pC" class="jN"><div class="cI"><h3 class="cT">Unlicensed indications or routes</h3><p>Several recommendations in this section involve unlicensed indications or routes.</p></div><div id="PHP121"><h2>Anorexia</h2><p>Anorexia may be helped by prednisolone 15–30 mg daily or dexamethasone 2–4 mg daily.</p></div><div id="PHP122"><h2>Bowel colic and excessive respiratory secretions</h2><p>Bowel colic and excessive respiratory secretions may be reduced by a subcutaneous injection of hyoscine hydrobromide 400 micrograms, hyoscine butylbromide 20 mg, or glycopyrronium 200 micrograms. These antimuscarinics are generally given every 4 hours when required, but hourly use is occasionally necessary, particularly in excessive respiratory secretions. If symptoms persist, they can be given regularly via a continuous infusion device, see <a title="target-block: BOWEL COLIC AND EXCESSIVE RESPIRATORY SECRETIONS" href="PHP130-continuous-infusion-devices.htm#PHP131">Bowel Colic and Excessive Respiratory Secretions</a>. Care is required to avoid the discomfort of dry mouth.</p></div><div><h2>Capillary bleeding</h2><p>Capillary bleeding can be treated with tranexamic acid (<a title="section: Antifibrinolytic drugs and haemostatics" href="PHP1589-antifibrinolytic-drugs-and-haemostatics.htm">section 2.11</a>) by mouth; treatment is usually discontinued one week after the bleeding has stopped, or, if necessary, it can be continued at a reduced dose. Alternatively, gauze soaked in tranexamic acid 100 mg/mL or adrenaline (epinephrine) solution 1 mg/mL (1 in 1000) can be applied to the affected area.</p><p>Vitamin K may be useful for the treatment and prevention of bleeding associated with prolonged clotting in liver disease. In severe chronic cholestasis, absorption of vitamin K may be impaired; either parenteral or water-soluble oral vitamin K should be considered (<a title="BNF:sub-section: Vitamin K" href="PHP6277-vitamin-k.htm">section 9.6.6</a>).</p></div><div id="PHP123"><h2>Constipation</h2><p>Constipation is a common cause of distress and is almost invariable after administration of an opioid analgesic. It should be prevented if possible by the regular administration of laxatives; a faecal softener with a peristaltic stimulant (e.g. co-danthramer) or lactulose solution with a senna preparation should be used (<a title=" Stimulant laxatives" href="PHP566-stimulant-laxatives.htm">section 1.6.2</a> and <a title=" Faecal softeners" href="PHP605-faecal-softeners.htm">section 1.6.3</a>). Methylnaltrexone (<a title="BNF:monograph: METHYLNALTREXONE BROMIDE" href="PHP665-methylnaltrexone-bromide.htm">section 1.6.6</a>) is licensed for the treatment of opioid-induced constipation.</p></div><div><h2>Convulsions</h2><p>Patients with cerebral tumours or uraemia may be susceptible to convulsions. Prophylactic treatment with phenytoin or carbamazepine (<a title=" Control of epilepsy" href="PHP2898-control-of-the-epilepsies.htm">section 4.8.1</a>) should be considered. When oral medication is no longer possible, diazepam as suppositories 10–20 mg every 4 to 8 hours, or phenobarbital by injection 50–200 mg twice daily is continued as prophylaxis. For the use of midazolam by subcutaneous infusion using a <a title="BNF:target-block: Syringe drivers and convulsions" href="PHP130-continuous-infusion-devices.htm#PHP132">continuous infusion device</a>, see below.</p></div><div id="PHP124"><h2>Dry mouth</h2><p>Dry mouth may be relieved by good mouth care and measures such as chewing sugar-free gum, sucking ice or pineapple chunks, or the use of artificial saliva (<a title=" Treatment of dry mouth" href="PHP7432-treatment-of-dry-mouth.htm">section 12.3.5</a>); dry mouth associated with candidiasis can be treated by oral preparations of nystatin or miconazole (<a title=" Oropharyngeal anti-infective drugs" href="PHP7380-oropharyngeal-anti-infective-drugs.htm">section 12.3.2</a>); alternatively, fluconazole can be given by mouth (<a title="BNF:sub-section: Triazole antifungals" href="PHP3698-triazole-antifungals.htm">section 5.2.1</a>). Dry mouth may be caused by certain medications including opioids, antimuscarinic drugs (e.g. hyoscine), antidepressants and some antiemetics; if possible, an alternative preparation should be considered.</p></div><div><h2>Dysphagia</h2><p>A corticosteroid such as dexamethasone 8 mg daily may help, temporarily, if there is an obstruction due to tumour. See also <a title="BNF:target-block: Dry mouth: palliative care" href="PHP120-miscellaneous-conditions.htm#PHP124">Dry Mouth</a>.</p></div><div><h2>Dyspnoea</h2><p>Breathlessness at rest may be relieved by regular oral morphine in carefully titrated doses, starting at 5 mg every 4 hours. Diazepam 5–10 mg daily may be helpful for dyspnoea associated with anxiety. A corticosteroid, such as dexamethasone 4–8 mg daily, may also be helpful if there is bronchospasm or partial obstruction.</p></div><div><h2>Fungating tumours</h2><p>Fungating tumours can be treated by regular dressing and antibacterial drugs; systemic treatment with metronidazole (<a title="BNF:monograph: METRONIDAZOLE" href="PHP3647-metronidazole.htm">section 5.1.11</a>) is often required to reduce malodour but topical metronidazole (<a title="BNF:monograph: METRONIDAZOLE" href="PHP7993-metronidazole.htm">section 13.10.1.2</a>) is also used.</p></div><div><h2>Hiccup</h2><p>Hiccup due to gastric distension may be helped by a preparation incorporating an antacid with an antiflatulent (<a title="target-text: Dimeticone for flatulence and hiccup" href="PHP276-antacids-and-simeticone.htm#PHP281">section 1.1.1</a>). If this fails, metoclopramide 10 mg every 6 to 8 hours by mouth or by subcutaneous or intramuscular injection can be added; if this also fails, baclofen 5 mg twice daily, or nifedipine 10 mg three times daily, or chlorpromazine (<a title="BNF:monograph: CHLORPROMAZINE HYDROCHLORIDE" href="PHP2213-chlorpromazine-hydrochloride.htm">section 4.2.1</a>) can be tried.</p></div><div><h2>Hypercalcaemia</h2><p>see <a title="BNF:sub-sub-section: Hypercalcaemia and hypercalciuria" href="PHP6106-hypercalcaemia-and-hypercalciuria.htm">section 9.5.1.2</a></p></div><div><h2>Insomnia</h2><p>Patients with advanced cancer may not sleep because of discomfort, cramps, night sweats, joint stiffness, or fear. There should be appropriate treatment of these problems before hypnotics are used. Benzodiazepines, such as temazepam (<a title="BNF:sub-section: Hypnotics" href="PHP2098-hypnotics.htm">section 4.1.1</a>), may be useful.</p></div><div id="PHP125"><h2>Intractable cough</h2><p>Intractable cough may be relieved by moist inhalations or by regular administration of oral morphine in an initial dose of 5 mg every 4 hours. Methadone linctus should be avoided because it has a long duration of action and tends to accumulate.</p></div><div id="PHP126"><h2>Nausea and vomiting</h2><p>Nausea and vomiting are common in patients with advanced cancer. Ideally, the cause should be determined before treatment with an antiemetic (<a title=" Drugs used in nausea and vertigo" href="PHP2505-drugs-used-in-nausea-and-vertigo.htm">section 4.6</a>) is started. A prokinetic antiemetic may be a preferred choice for first-line therapy.</p><p>Nausea and vomiting may occur with opioid therapy particularly in the initial stages but can be prevented by giving an antiemetic such as haloperidol or metoclopramide. An antiemetic is usually necessary only for the first 4 or 5 days and therefore combined preparations containing an opioid with an antiemetic are not recommended because they lead to unnecessary antiemetic therapy (and associated side-effects when used long-term).</p><p>Metoclopramide has a prokinetic action and is used in a dose of 10 mg 3 times daily by mouth for nausea and vomiting associated with gastritis, gastric stasis, and functional bowel obstruction. Drugs with antimuscarinic effects antagonise prokinetic drugs and, if possible, should not be used concurrently.</p><p>Haloperidol is used by mouth in an initial dose of 1.5 mg once or twice daily (can be increased if necessary to 5–10 mg daily in divided doses) for most metabolic causes of vomiting (e.g. hypercalcaemia, renal failure).</p><p>Cyclizine is given in a dose of 50 mg up to 3 times daily by mouth. It is used for nausea and vomiting due to mechanical bowel obstruction, raised intracranial pressure, and motion sickness.</p><p>Levomepromazine is used as an antiemetic; it is given by mouth or by subcutaneous injection in an initial dose of 6 mg or 6.25 mg at bedtime, titrated if necessary to 12.5–25 mg twice daily (6-mg tablets available from <a title="BNF:appendix: Special-order Manufacturers" href="PHP10403-special-order-manufacturers.htm">‘special-order’ manufacturers or specialist importing companies</a>). For the dose by subcutaneous infusion, see <a title="BNF:target-block: nausea vomiting palliative care" href="PHP130-continuous-infusion-devices.htm#PHP133">Nausea and vomiting</a>. Dexamethasone 8–16 mg daily by mouth can be used as an adjunct.</p><p>Antiemetic therapy should be reviewed every 24 hours; it may be necessary to substitute the antiemetic or to add another one.</p><p>For the administration of antiemetics by subcutaneous infusion using a <a title="BNF:target-block: nausea vomiting palliative care" href="PHP130-continuous-infusion-devices.htm#PHP133">continuous infusion device</a>, see below.</p><p>For the treatment of nausea and vomiting associated with cancer chemotherapy, see <a title=" Cytotoxic drugs" href="PHP5180-cytotoxic-drugs.htm">section 8.1</a>.</p></div><div id="PHP127"><h2>Pruritus</h2><p>Pruritus, even when associated with obstructive jaundice, often responds to simple measures such as application of emollients (<a title=" Emollients" href="PHP7459-emollients.htm">section 13.2.1</a>). In the case of obstructive jaundice, further measures include administration of colestyramine (<a title="monograph: COLESTYRAMINE" href="PHP727-colestyramine.htm">section 1.9.2</a>).</p></div><div id="PHP128"><h2>Raised intracranial pressure</h2><p>Headache due to raised intracranial pressure often responds to a high dose of a corticosteroid, such as dexamethasone 16 mg daily for 4 to 5 days, subsequently reduced to 4–6 mg daily if possible; dexamethasone should be given before 6 p.m. to reduce the risk of insomnia.</p></div><div id="PHP129"><h2>Restlessness and confusion</h2><p>Restlessness and confusion may require treatment with an antipsychotic, e.g. haloperidol 2 mg by mouth or 2.5 mg by subcutaneous injection, or levomepromazine 6 mg by mouth or 6.25 mg by subcutaneous injection, both repeated every 2 hours if required. The dose and frequency is adjusted according to the level of patient distress and the response. A regular maintenance dose should also be considered, given twice daily either by mouth or by subcutaneous injection; alternatively use a continuous infusion device, see <a title="target-block: RESTLESSNESS AND CONFUSION" href="PHP130-continuous-infusion-devices.htm#PHP135">Restlessness and Confusion</a>.</p></div></div><?highlighter off?><div id="pE">◄ <a accesskey="[" href="PHP114-pain.htm">Previous: Pain</a> | <a class="top" href="PHP120-miscellaneous-conditions.htm#">Top</a> | <a accesskey="]" href="PHP130-continuous-infusion-devices.htm">Next: Continuous infusion devices</a> ►</div></div></div><div id="pF"><div id="pL"><div id="footer"><div id="footerinner"><ul><li><a accesskey="0" href="accessibility.htm" title="Accessibility information: access key 0">Accessibility</a> | </li><li><a href="http://www.medicinescomplete.com/mc/marketing/current/contact.htm">Contact Us</a> | </li><li><a href="privacy.htm" title="Cookie and Privacy Policy">Cookie and Privacy Policy</a> | </li><li><a accesskey="3" href="http://www.medicinescomplete.com/mc/sitemap.htm" title="Site Map: access key 3">Site Map</a> | </li><li><a accesskey="8" href="terms.htm" title="Terms and Conditions: access key 8">Terms and Conditions</a></li></ul></div></div></div><div id="pX"><p><a href="PHP0-publication-information.htm" rel="copyright">Copyright © BMJ Group and Pharmaceutical Press 2012. All rights reserved. </a></p></div></div><script type="text/javascript">$(document).ready(function(){$.ga('UA-9959526-1');});</script></body></html>